基石药业-B(02616.HK)avapritinib针对晚期GIST的I/II期桥接注册性试验完成中国首例受试者给药
基石药业-B(02616.HK)公布,由基石药业合作夥伴 Blueprint Medicine
Corporation(纳斯达克股份代号:BPMC)(「Blueprint」)开发的avapritinib 的I/II期桥接注册性试验实现中国首例受试者给药。这是一项中国单独的桥接注册性研究,包括I期剂量递增和II期剂量扩展试验,目的是评估avapritinib在不可手术切除或转移性胃肠道间质瘤(「GIST」)患者中的安全性、药代动力学和疗效。该试验将包括PDGFRA D842V基因驱动的GIST和二线、三线及以上的GIST患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.